Neurocycle Therapeutics currently has two major lines of research. Both focus on subtype-selective modulation of the GABAA receptor, but achieve it by interacting at different binding sites. This enables each program to achieve a unique selectivity profile that optimizes them for use in our targeted indications.  

The first focuses on developing new subtype-selective GABAA receptor modulators that interact at the benzodiazepine binding site. Our non-sedating compounds are currently being developed as novel treatments of pruritus and pain. Our itch candidate, NCT-10004, has succesfully completed human phase 1 single ascending dose studies, and our lead compound for neuropathic pain, NCT-10001, is at the candidate-selection stage.

Our second line of research focuses on the discovery of new, orally-active, α1-sparing neurosteroids for  treatment of refractory epilepsies and postpartum depression. We are using our biocatalytic drug optimization platform to address metabolic stability problems often present with this class of drugs.

Target Indications


Neuropathic Pain